News Chart Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 21:00:00 02/07/2026 BST			5-day change	1st Jan Change
3.630 ^USD	+4.91%		+19.41%	+32.00%

06-03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
06-03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

93a650e54487a9f80acdcfb2d1.-RU9CRePHoC2W-1Fvq_xmF8oE8Ez8BnegsI9eMmfgGo.yyBxOn3XRsvwH68s9MCerG1-XK1fwH6RyvJVTq7s7li9R3xMecMm-e4JrA~0173067d71c8fa0fdaf56adefd67c254